Consideration of Capital Enhancement Measures to Eliminate Negative Net Worth
First written in FY2019-Q2. 6 of 9 entries say "Advanced", first in FY2019-Q3. Latest entry: FY2022-Q2.
The whole theme swung hardest in 2020: 2 of 9 companies on the "Worse" side.
1 other company's latest entry also says "Advanced".
- FY2022-Q2AdvancedAnnual report
「During the cumulative second quarter of the current fiscal year, the number of issued shares increased by 1,000,000 through the issuance of new shares upon exercise of the Ninth Series Stock Acquisition Rights, which are subject to an adjustment provision for the exercise price. Capital stock and capital surplus each increased by ¥299,042 thousand.」
A cumulative 1,000,000 shares under the Ninth Series Stock Acquisition Rights had been exercised, increasing capital stock and capital surplus by ¥299 million each. Financing for investment and debt reduction progressed, strengthening the financial base following elimination of the capital deficit. - FY2022-Q1AdvancedAnnual report
「During the cumulative first quarter of the current fiscal year, the number of issued shares increased by 295,000 through the issuance of new shares upon exercise of the Ninth Series Stock Acquisition Rights, which are subject to an adjustment provision for the exercise price. Capital stock and capital surplus each increased by ¥98,788 thousand.」
Exercise of the Ninth Series Stock Acquisition Rights resulted in the issuance of 295,000 shares, increasing capital stock and capital surplus by ¥98.8 million each. An additional 320,000 shares had been issued by the filing date. - FY2021ReframedAnnual report
「Use of proceeds: ① Capital expenditure related to commercialising nanoscale zeolite: ¥400,000 thousand ② Reduction of interest-bearing debt: ¥352,680 thousand Total: ¥752,680 thousand」
The focus shifted from the previous capital strengthening measures, whose primary purpose was to eliminate the capital deficit, to financing through the Ninth Series Stock Acquisition Rights for capital expenditure on nanoscale zeolite and reduction of interest-bearing debt. - FY2020-Q3AchievedAnnual report
「The remaining 100,000 shares were exercised on 6 January 2020, completing the exercise of all 5,000,000 shares. The total funds raised through these stock acquisition rights were ¥2,911,185 thousand.」
The remaining 100,000 shares under the third-party allotment stock acquisition rights were exercised on 6 January 2020, completing the exercise of all 5 million issued shares and raising a total of ¥2,911 million. - FY2020-Q2AdvancedAnnual report
「During the current second quarter, the stock acquisition rights relating to bonds with stock acquisition rights subject to an adjustment provision for the exercise price were exercised as follows.」
Exercise of the Sixth and Seventh Series Stock Acquisition Rights raised ¥419 million from 1,018,000 rights during the quarter, bringing the cumulative totals to 3,000,000 rights and ¥1,570 million. In addition, exercise of all Seventh Series Stock Acquisition Rights was completed as of 1 November 2019. - FY2020-Q1AdvancedAnnual report
「Number of such bonds with stock acquisition rights subject to an adjustment provision for the exercise price exercised during the current first quarter: 1,302,000; number of shares delivered upon exercise during the current first quarter: 1,302,000; funds raised through exercises during the current first quarter: ¥692,082 thousand」
A total of 1,302,000 stock acquisition rights issued through a third-party allotment were exercised, raising ¥692 million. Cumulatively, 1,982,000 rights had been exercised and ¥1,151 million had been raised, marking further progress in the capital strengthening measures. - FY2019AdvancedAnnual report
「The Company requested that its lending financial institutions defer repayment of loan principal and, as of the date of submission of this annual securities report, had obtained the consent of each financial institution.」
The capital strengthening measures through third-party allotment stock acquisition rights progressed to the exercise phase, and the financial institutions consented to deferment of repayments. By the end of May 2019, slightly more than 40% of the Sixth Series Stock Acquisition Rights had been exercised. - FY2019-Q3AdvancedAnnual report
「To raise the funds necessary for continuing operations and establishing a stable earnings base, the Company resolved at a Board of Directors meeting held on 27 December 2018 to issue stock acquisition rights through a third-party allotment with an adjustment provision for the issue price, with an allotment date of 15 January 2019. The Company planned to raise approximately ¥3,449 million.」
The plan progressed from consideration of capital strengthening measures to a Board resolution to issue stock acquisition rights allotted on 15 January 2019, making the planned ¥3,449 million financing concrete. Subsequent-event disclosure also reported completion of payment and drawdown of a ¥585.6 million loan. - FY2019-Q2First statedAnnual report
「To eliminate the capital deficit, the Company will consider implementing capital strengthening measures to raise the funds necessary for continuing operations and establishing a stable earnings base.」
To eliminate the capital deficit and secure funds necessary for continuing operations, the Company newly indicated that it was considering capital strengthening measures. Although it had obtained the understanding of its main lending bank regarding support, no commitment had been made as of that time.